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Outcomes of Stereotactic Ablative Radiotherapy for
Centrally Located Early-Stage Lung Cancer
Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J. Slotman, MD, PhD,
and Suresh Senan, MRCP, FRCR, PhD
Introduction: The use of stereotactic ablative radiotherapy (SABR) in
centrally located early-stage lung tumors has been associated with
increased toxicity. We studied outcomes after delivery of risk-adapted
SABR of central tumors.
Methods: SABR was delivered in eight fractions of 7.5 Gy to 63
such patients between 2003 and 2009. Of these, 37 patients had a
tumor at a central hilar location, whereas 26 patients had tumors
abutting the pericardium or mediastinal structures. Survival out-
comes were compared with patients with peripheral tumors treated
during the same time period using fewer fractions of SABR.
Results: Median follow-up was 35 months. Late grade III toxicity
was limited to chest wall pain (n  2) and increased dyspnoea (n 
2). No grade IV/V toxicity was observed, but grade V toxicity could
not be excluded with certainty in nine patients who died of cardio-
pulmonary causes. Distant metastases were the predominant cause
of death; cardiovascular deaths were not associated with a paracar-
dial tumor location. No significant differences in outcomes were
observed between these 63 patients and 445 other SABR patients
treated for peripheral early-stage lung tumors. Three-year local
control rates were 92.6% and 90.2% (p  0.9). Three-year overall
survival rates were 64.3% and 51.1% with median survival rates of
47 and 36 months, in favor of the group of patients with central
tumors (p  0.09).
Conclusions: Use of risk-adapted SABR delivered in eight fractions
of 7.5 Gy did not result in excess toxicity for centrally located
early-stage lung tumors, and clinical outcomes were comparable
with those seen for peripheral lesions.
Key Words: Stereotactic radiotherapy, SABR, SBRT, Early stage
lung cancer, Toxicity.
(J Thorac Oncol. 2011;6: 2036–2043)
Non-small cell lung cancer (NSCLC) is the leading causeof cancer related mortality worldwide, with more than 1
million deaths every year.1 Surgery is widely considered to be
the treatment of choice in fit patients who present with
early-stage disease.2 In patients with significant comorbidity
who are at increased risk of surgical morbidity and mor-
tality, stereotactic body radiation therapy (SBRT), nowa-
days known as stereotactic ablative radiotherapy (SABR),
is increasingly considered as a standard treatment alterna-
tive.3–6 SABR is a form of high-precision radiotherapy,
characterized by the use of extremely high biological doses
of radiation delivered in a few fractions, usually between 3
and 8 in a 2- to 3-week period.7
Most available data on SABR outcomes has been
derived from treating small, peripherally located early-
stage lung tumors, where local control rates in excess of
85% were reported with very low toxicity.8,9 Studies eval-
uating SABR for peripheral lesions have reported an inci-
dence of total toxicities, both acute and late, of less than
10%.4 Nevertheless, some reports of outcomes after treat-
ment for centrally located lung tumors with SABR suggest
cause for concern. One cited a 2-year freedom from severe
toxicity of only 54% when SABR fraction doses ranging
from 20 to 23 Gy were used.10 Another group reported a
33% incidence of grades III to IV toxicity in nine patients
with central tumors.11
The effect of radiation schedules can be recalculated
and expressed as biologically effective dose (BED10 for
tumor and BED3 for normal tissues).12 The total dose ex-
pressed as BED can be used to compare different dose
schedules. Conventionally fractionated schedules typically
use doses with a BED10 for tumor tissue of approximately 70
to 80 Gy. Modern SABR schedules use dose schedules
equivalent to a BED10 of at least 100 to 105 Gy to achieve
very high local control rates.9,13 Achieving this BED10 with-
out excessive toxicity for central tumors requires the use of
lower doses per fraction, as fractionation relatively decreases
the dose (BED3) for normal tissues. Since 2003, we consis-
tently applied such a “risk adapted” SABR approach using
smaller fraction sizes for tumor locations that overlapped
normal organs at risk for toxicity.8 For target volumes over-
lapping the central hilus, heart, or mediastinal structures, we
applied eight fractions of 7.5 Gy. The present report analyzes
the clinical outcomes of this treatment schedule.
Department of Radiation Oncology, VU University Medical Center, Amster-
dam, The Netherlands.
Disclosure: Department of Radiation Oncology, VU University Medical
Center has a Master Research Agreement with Varian Medical Systems.
S.S., B.J.S., and F.J.L. have received speakers honoraria from Varian
Medical Systems. C.J.A.H.: no financial disclosures.
Address for correspondence: Cornelis J. A. Haasbeek, MD, PhD, Department
of Radiation Oncology, VU University Medical Center (VUMC), de
Boelelaan 1117, Amsterdam 1081 HV, The Netherlands. E-mail:
cja.haasbeek@vumc.nl
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0612-2036
Journal of Thoracic Oncology • Volume 6, Number 12, December 20112036
MATERIALS AND METHODS
Details of all SABR patients and treatments performed
for early-stage NSCLC at the VU University Medical Center
are entered into a prospective database. For this study, we
evaluated patients with tumors in high-risk locations. Patients
at “high risk” were defined by tumors (i) located in the
proximal bronchial tree zone as defined by the Radiation
Therapy Oncology Group10,14 and/or (ii) located 1 cm from
the heart or mediastinum (Figure 1). The proximal bronchial
tree includes the carina, right and left main bronchi, right and
left upper lobe bronchi, intermedius bronchus, right middle
lobe bronchus, lingular bronchus, and right and left lower lobe
bronchi; the proximal bronchial tree zone extends 2 cm in all
directions. Patients in whom the planning target volume (PTV)
overlapped with the esophagus were excluded from SABR.
Tumors adjacent to the brachial plexus, for which this risk-
adapted schedule was also applied, were excluded from the
current analysis as plexopathy was not considered a potentially
fatal complication.
A total of 63 patients fulfilled the inclusion criteria. Pa-
tients were treated between 2003 and 2009 and were all classi-
fied at that time as having stage I NSCLC using the Union for
International Cancer Control tumor, node, metastasis classifica-
tion version 6. In the recently introduced classification system
version 7, 17 patients would currently be staged as stage II by
tumor size exceeding 5 cm.15 Patient characteristics are summa-
rized in Table 1. Staging by 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET) scan was performed in all
patients to rule out regional and distant metastasis. Patients with
suspected tumor-positive lymph nodes were not accepted for
SABR treatment. Histological confirmation of the new primary
lung tumor was obtained in 24 of 63 patients (38.1%). The
diagnosis in other patients was made by a multidisciplinary
tumor board based in all cases on a new or growing, FDG-PET-
positive lesion with radiological characteristics of malignancy.
Two previous prospective clinical trials in similar Dutch popu-
lations in our region,16,17 as well as a single institution Dutch
study,18 revealed that the likelihood of a benign diagnosis with
such a presentation was less than 5%. All patients were consid-
ered inoperable, and inoperability was assessed by a multidisci-
plinary tumor board, which often included a thoracic surgeon.
Most patients had combinations of cardiac, pulmonary, and
other comorbidities as reason for inoperability. The mean pre-
SABR lung function, measured as the forced expiratory volume
in 1 second, was 68.0% of predicted (range: 25–118%).
4DCT Scanning Procedure
The 4DCT scanning procedure used at our center has
been reported in detail previously.19,20 Briefly, respiration-
correlated 4DCT scans were performed during uncoached
quiet respiration using the Real-Time Position Management
system (RPM, Varian medical systems, Palo Alto, CA) and a
FIGURE 1. Patient examples with early-stage non-small cell lung cancer (NSCLC) in central tumor locations: (A) tumor adja-
cent to the aortic arch, (B) tumor adjacent to the left ventricle, and (C) tumor in a hilar location, extending to the chest wall.
The patient in panel (C) is the patient who developed a rib fracture after treatment.
TABLE 1. Patient, Tumor, and Treatment Characteristics
Patients 63
Gender Male: 42 (67%)
Female: 21
Median age 74 (range: 47–87)
COPD GOLD scorea
No COPD 16 patients
I—mild 6
II—moderate 20
III—severe 19
IV—very severe 2
WHO performance score
0 5 patients
I 38
II 19
III 1
Histology 24 patients
Squamous 8
Adeno 4
NSCLC not specified 12
No histology 39
Tumor diameter, median (range) 36 (15–74)
0–2 cm 5
2–3 cm 12
3–5 cm 29
5–7 cm 15
7 cm 2
PTV size, median (range) 43.6 ml (9.7–189.2 ml)
Fields (noncoplanar), median (range) 10 (7–11)
a The severity of chronic obstructive pulmonary disease (COPD) using the GOLD
scoring system (http://goldcopd.com).
NSCLC, non-small cell lung cancer; PTV, planning target volume; WHO, World
Health Organization.
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16-slice computed tomography (CT) scanner (Lightspeed 16
GE Medical Systems, Waukesha, WI). Data were acquired
for each couch position for at least the duration of a full
respiratory cycle. Retrospective sorting of the images into
spatiotemporally coherent volumes was performed using Ad-
vantage 4D software (GE Medical Systems, Waukesha, WI).
Each reconstructed image was assigned to a specific respira-
tory phase (or “bin”), resulting in 10 CT sets each reflecting
10% of the respiratory cycle.21
Generating Target Volumes
Internal target volume (ITV; ICRU 62) was delineated
on a single maximum intensity projection CT set (MIP),
which is derived from the 4DCT.22 As an overlapping trajec-
tory of the tumor with an adjacent high-density structure can
lead to problems especially in centrally located tumors with
overlapping bronchi, large blood vessels, and mediastinal
structures, delineated MIPs were reviewed by projecting the
ITV onto the other 4DCT bins or at least checked with the CT
bins corresponding to the extreme inhale and exhale posi-
tions of the tumor. In difficult cases with overlapping hilar
structures, a second 4DCT scan limited to the tumor area
was performed after administration of intravenous contrast
to facilitate delineation.23 Isotropic margins of 3 mm were
used to derive the PTV from the ITV. No separate margins
were used to account for microscopic tumor extension.7
Staging FDG-PET scans were not used for purposes of
target delineation.
Dose Schemes and Treatment Delivery
All included patients were treated using a risk-adapted
scheme of eight fractions of 7.5 Gy to a total dose of 60 Gy,
prescribed at the 80% PTV encompassing isodose. At least
99% of the PTV volume was covered by the prescription
isodose. Dose reductions of the PTV to spare overlapping
critical structures were not used.
SABR was planned with Brainscan software (BrainLab
AG, Heimstetten, Germany), and treatments were delivered
using a Novalis linear accelerator using 7 to 11 (median 10)
noncoplanar radiation beams with micromultileaf shielding.
For patients reported in the current cohort, the ability to
perform a conebeam CT with soft tissue setup was unavail-
able. Patient position was checked and corrected before each
treatment fraction using orthogonal x-ray imaging devices
integrated in the linear accelerator room (Exactrac system,
Brainlab AG) and a Robotics treatment couch (Brainlab AG),
which enables correction of both translational and rotational
shifts.
Follow-Up
All patients underwent routine serial CT scans at 3, 6,
and 12 months, followed by yearly CT scans thereafter.8
FDG-PET scans were performed in case of suspected local,
regional, or distant recurrence. If necessary, additional clin-
ical follow-up information was obtained from the general
practitioner and/or pulmonary physician. Complete survival
data were obtained using Dutch civil records, which cover the
entire Dutch population and contain all deaths since 1811.
Statistical Analysis
Statistical analysis was performed using SPSS 15.0.0
(SPSS Inc., Chicago, IL) and Microsoft Office Excel 2003
(Microsoft Corp., Redmond, WA) software. Survival was
calculated from the date of first SABR treatment.
Comparison with Peripheral Tumors
The survival outcomes of patients with central tumors
were compared with the group of patients with peripheral
tumors treated by SABR in our institute in the same period of
time with identical treatment techniques except for the used
dose schedules. Peripheral tumors were treated to three frac-
tions of 20 Gy for T1 tumors; patients were treated to five
fractions of 12 Gy for T2 tumors and for T1 tumors directly
adjacent to the chest wall.
RESULTS
Sixty-three patients had tumors located in a high-risk
location. Thirty-seven tumors were located in a hilar, central
location within 2 cm of the proximal bronchial tree. The
remaining 26 patients who had tumors located outside the
region of the proximal bronchial tree were nevertheless con-
sidered to be at high risk due to overlap with other high-risk
mediastinal structures (Table 2).
Early Toxicity
Fifty-six patients (89%) reported no or grade I tox-
icity (CTCAE V3.0); six patients (10%) reported grade II
toxicity, and only one patient (2%) reported grade III acute
toxicity (Table 3). The patient with grade III symptoms
required temporary treatment for nonspecific chest wall
pain with opioids, despite the fact that the tumor did not
extend to the chest wall, and the high-dose regions were
not in the chest wall.
Late Toxicity
Fifty patients (79%) reported no or grade I late toxicity
(3 months after treatment); nine patients (14%) reported
grade II toxicity, and four patients (6%) reported grade III
toxicity (Table 3). One patient presenting with grade
II toxicity had a bronchial stenosis with atelectasis and
symptomatic cough 3.5 years after treatment. No evidence for
tumor recurrence was found at bronchoscopy and on a FDG-
PET, and no medical intervention was indicated in this
patient. In two patients, grade III toxicity manifested due to
increased dyspnea, one patient had a rib fracture and one
TABLE 2. Tumor Location
Tumor Locationa No. of Patients
Proximal bronchial tree 37
Pericardium 11
Overlap other mediastinal structures 15
Aorta 6
Near esophagus 2
Other 7
a Many tumors are near multiple structures. The area with predominant overlap was
chosen as primary location.
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presented with nonspecific chest wall pain. The latter is same
patient who developed early grade III chest wall pain. Three
patients with grade III toxicity had tumors below the median
tumor size (36 mm), and the patient with the rib fracture had
a tumor with a diameter of 7 cm extending from the central
hilus up to the chest wall (Figure 1). No grade IV or clear
grade V toxicity was observed.
Cause of Death
Thirty-nine of the 63 patients (62%) were still alive at
time of analysis. Of the 24 patients who had died, 14 patients
died of tumor progression, and one patient died of acquired
immune deficiency syndrome-related complications. The re-
maining nine patients died at a median age of 79 years, and
their deaths were attributed by their physician to cardiac
events (five patients), respiratory failure (three patients), or
unknown (one patient). Causes of death were not related to
tumor location. Of five patients who died of possible cardiac
failure, one had a target volume overlapping the pericardium,
three were located in the proximal bronchial tree zone, and
one was located against the upper mediastinum but not
adjacent to the heart muscle or coronary vessels. The only
patient who died of a cardiac cause and had overlap with the
pericardium had chronic atrial fibrillation and a severe pre-
treatment aortic valve stenosis. His planned aortic valve
replacement was postponed because of his lung cancer until
his death almost 2.5 years after SABR. In the three patients
who died of possible respiratory failure, only one tumor was
located in the hilus, one was located next to the ascending
aorta, and one next to the descending aorta. The pretreatment
pulmonary function of these patients was comparable with
the other patients. The patient with an unknown cause of
death had a tumor located near the right hilus in the proximal
bronchial tree zone.
Survival Outcomes
For the 63 patients with central tumors, 1, 2- and 5-year
overall survival rates were 85.7%, 69.0%, and 49.5%, respec-
tively. Four local failures were observed resulting in actuarial
local control rates at 1, 2, and 5 years of 94.8%, 92.6%, and
92.6%, respectively. All four patients with local failure had a
tumor diameter exceeding 3 cm. Only one patient had a
suspected isolated local recurrence, the other three patients
also had regional or distant metastases (Figure 2). The sus-
pected local recurrence in the single patient with an isolated
local recurrence was based on a growing lesion at CT inves-
tigation. Nevertheless, this patient died of respiratory insuf-
ficiency without further investigations being performed, or
pathological proof of recurrence, 6 months later at the age of
84 years.
Five regional failures were seen, resulting in actuarial
regional control rates at 1, 2, and 5 years of 93.0%, 91.1%,
and 91.1%, respectively. No isolated regional recurrences
were observed. Fifteen patients had distant failure, with
actuarial distant control rates at 1, 2, and 5 years of 85.7%,
76.0%, and 72.7%, respectively. Disease-free survival rates at
1, 2, and 5 years were 82.3%, 74.3%, and 71.0%, respec-
tively. Univariate analysis of possible predictive factors for
overall survival showed improved survival for women, with
2-year overall survival of 79.6% versus 34.8% for men (p 
0.045). All other studied predictive factors and outcome
measures (proof of malignancy, T stage, tumor location,
GOLD class, comorbidity scores, World Health Organization
performance score, and earlier malignancies) did not show
significant correlations, although the lack of histological
proof of malignancy showed a trend toward inferior disease-
free survival.
Comparison with Peripheral Tumors Treated
with SABR
Clinical outcomes of the 63 patients with central tumors
were compared with 445 patients with peripheral early-stage
lung tumors. The median follow-up was 35 months for both
groups (range: 13–86 months). Both groups were well bal-
FIGURE 2. Local, regional, and distant failure rates for cen-
tral early-stage lung tumors after stereotactic ablative radio-
therapy (SABR).
TABLE 3. Early and Late Toxicity After SABR in 63 Patients
with Central Stage Early-Stage NSCLC (Absolute Patient
Numbers)
Acute Toxicity Late Toxicity (>3 mo)
I II III I II III
Dyspnea 5 2 — 3 2 2
Chest wall pain 3 1 1 4 2 1
Fatigue 10 1 — 4 1 —
Coughing 5 — — — — —
Nausea 3 — — — — —
Radiation dermatitis 1 1 — — 1 —
Hemoptysis 1 1 — — 1 —
Esophagitis 1 — — — — —
Pleural effusion — — — — 1 —
Rib fracture — — — — — 1
Bronchial stenosis — — — — 1 —
Total (% of patients) 29 (62) 6 (10) 1 (2) 11 (17) 9 (14) 4 (6)
SABR, stereotactic ablative radiotherapy; NSCLC, non-small cell lung cancer.
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anced regarding gender, age, GOLD class, proof of malig-
nancy, and World Health Organization performance scores.
Median tumor diameter was larger for the central tumor
group (median: 36 mm versus 26 mm; p  0.001). No
significant differences were observed in survival outcomes
between the 63 patients with central and the 445 patients with
peripheral tumors (Figure 3). The 3-year overall survival
rates for patients with central versus peripheral tumors were
64.3% and 51.1%, with median survival rates of 47 and 36
months, respectively (p  0.09). Three-year local control
rates were 92.6% and 90.2% (p  0.9), regional control
91.1% and 86.2% (p  0.47), distant control 72.7% and
75.2% (p 0.72), and 3-year disease-free survival rates were
69.9% and 67.8% (p  0.91), respectively.
DISCUSSION
The treatment of patients with early stage, centrally
located lung tumors who are unfit for surgery is challenging.
Outcomes of conventional radiotherapy are poor due to high
rates of local failure, but the use of SABR for centrally
located tumors has been reported to be associated with
increased toxicity when the SABR schedules commonly used
for peripheral tumors were applied.10 Nevertheless, the avail-
able data on SABR for centrally located tumors has largely
been limited to small series with generally limited follow-up
(summarized in Table 4), and most of these series consist of
a mix of patients with NSCLC in central and peripheral
locations, or patients with centrally located pulmonary me-
tastasis, without reporting separate data for central lung
tumors. Our present report on long-term results in 63 patients
with early-stage NSCLC using a standardized schedule of 60
Gy in eight fractions, represents the largest such report to
date. Our main conclusion is that SABR can achieve cures in
patients with central, high-risk tumors with a low incidence
of high-grade toxicity.
The relatively high local control rates and low toxicity
observed in our series is consistent with the known relation-
ships between local control, toxicity and biological effective
doses (BED) as shown in Figure 4. The data were extrapo-
lated from the published series summarized in Table 4.
Despite the small patient numbers, Figure 4A reveals the
same trend toward higher local control at higher BEDs as was
reported for peripheral tumors, with local control rates more
than 90% using schedules with a BED10 above 100 Gy. The
BED10 of our 60 Gy in eight fraction schedule is equivalent
to 105 Gy for tumor tissue. Figure 4B shows the trend toward
higher toxicity rates at higher doses. The BED3 for normal
tissue in our series was 210 Gy, equivalent to 126 Gy in 2 Gy
fractions, which is at the low end of the fractionation sched-
ules reported in the literature.
In a group of 22 patients, Timmerman et al.10 reported
an actuarial 2-year severe toxicity rate of 46% for centrally
located primary lung tumors. Nevertheless, these authors
used an estimated BED10 far in excess of the approximately
100 Gy required for local control in early-stage NSCLC,9,12,24
as 60 to 66 Gy was delivered in three fractions (BED10 
180–211 Gy for tumor; BED3 460–550 Gy for normal
tissue). If one assumes that the linear-quadratic model for
BED calculation is appropriate for high fraction doses, these
schedules were equivalent to more than 275 Gy in 2 Gy
fractions for normal tissue, which is more than twice that
delivered in our eight-fraction schedule. Nevertheless, a sub-
sequent publication by the same authors with longer follow-
up, reported no statistically significant differences in toxicity
between central and peripheral tumors, and an identical
survival for the group of 22 central tumors to their group of
patients with peripheral tumors.25
Song et al.11 also reported increased toxicity when
treating central tumor locations with a short schedule of three
to four fractions on consecutive days. Grades III to V toxicity
was seen in three of nine patients, and eight of nine patients
had radiological evidence of partial or complete bronchial
strictures after a median time of 20 months. One patient died
after an intervention for a complete bronchial stenosis. Nev-
ertheless, no significant location-dependent differences in
overall survival were found, with a 2-year overall survival
rate of 50% versus 35%, in favor of the group of patients with
central tumors. In the series reported by Bral et al.,26 one
patient with a central lesion died after an intervention for a
bronchial stenosis, which suggests that invasive procedures in
highly irradiated bronchial tissues after SABR carries an
increased risk of toxicity.
Our study found low levels of grade III, no grade IV,
and no clear grade V toxicity. We only saw one grade II
bronchial stricture, and no intervention was needed. Never-
theless, nine patients died of cardiac or pulmonary causes
without tumor progression. Although we could not relate
tumor location to the probable cause of death, we cannot
completely exclude grade V toxicity as cause of death in
these nine patients. Had the use of SABR for central lesions
been as dangerous as was suggested previously, the resulting
median survival in patients with central tumors after SABR
would be expected to be much lower than for patients with
FIGURE 3. Overall survival for central and peripheral early-
stage lung tumors after stereotactic ablative radiotherapy
(SABR).
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peripheral tumors. When comparing our results for central
tumors with that seen for 445 SABR patients treated in the
same time period for peripheral tumors in our institute, no
survival decrease was seen for patients treated for central
tumors (Figure 3). These findings are reassuring, particularly
in the light of comparable SABR results from peripheral
tumors in 13 reports using BED values above 100 Gy.27 The
survival observed in our patients with central tumors is higher
than in 9 of 13 of these series in the review, with only the four
Japanese series reporting higher survival rates.
Dose-dependent late bronchial, cardiac, and esophageal
toxicity has been reported after conventionally fractionated
high-dose radiotherapy or chemoradiotherapy for lung tu-
mors.28,29 The toxicity risk after SABR in our series is
acceptable at a median follow-up of 35 months, but we
acknowledge that late bronchial stenosis or cardiac problem
might still arise after even longer follow-up. Nevertheless,
medically inoperable patients with centrally located tumors
have few alternative treatment options. In addition, the results
have to be viewed in the light of the alternative scenarios,
specifically the surgical mortality of centrally located lung
cancer of up to 10% for pneumonectomies,30 the unaccept-
able death rate from tumor progression after conventional
radiotherapy,31 or no curative treatment.
A shortcoming of this study, and most studies in SABR
literature, is the lack of histological proof of malignancy in a
majority of patients, although surgical series show that the
chance of treating benign disease in the Netherlands is below
5% as pointed out earlier.16–18 Our study population reflects
current clinical practice where pathological proof is pre-
ferred but not obtained at all costs in our frail, inoperable
patient groups. This issue is important in areas with a
higher prevalence of benign disease and will become extra
important in future when more very small lesions will be
detected by screening. As routine screening has not yet
been implemented in the Netherlands, the smallest lesion
in our series was 15 mm.
Safety data from our study indicate that SABR should
continue to be evaluated for centrally located tumors using
optimal 4DCT-based treatment planning and delivery, in
conjunction with schemes with a BED10 for tumor of around
100 to 110 Gy, and a relatively low BED3 for normal tissues.
The Radiation Therapy Oncology Group 0813 study is cur-
rently accruing patients with central, pathology-proven early-
stage lung tumors in a dose escalation approach and will take
several years to accrue and attain long enough follow-up to
estimate long-term toxicity. The European Organization for
Research and Treatment of Cancer is also planning a similar
study including pathology-proven central tumors, based on
the preliminary results of this study. A recent population-
based study indicates that an increasing number of elderly,
unfit patients are referred for potentially curative SABR
therapy than when only conventional radiotherapy is avail-
able.6 The growing experience with SABR for central tumors
can also be expected to lead to further improvements in
population-based survivals in early-stage lung cancer.
CONCLUSIONS
In medically inoperable patients with a centrally lo-
cated early-stage lung cancer, the use of risk-adapted stereo-
tactic radiation therapy using a dose scheme of eight fractions
of 7.5 Gy is an effective treatment with acceptable toxicity.
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